AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics, provides an update on the performance of the AffiDX® SARS-CoV-2 antigen lateral flow test (LFT) with the Omicron variant.

Ziath reports how its super-fast 2D barcode rack readers are assisting COVID-19 testing lab – SummerBio LLC to offer rapid, low-cost, high-volume testing solutions for educational organizations, employers and laboratories.

Evotec SE has announced that the Company has been selected by the German Federal Ministry of Education and Research to receive a grant for the development of a potential first-in-class immunomodulatory therapy against COVID 19.

Ziath reports how its super-fast 2D barcode rack readers are assisting a leading COVID-19 testing lab to offer rapid, low-cost, high-volume testing solutions for educational organizations, employers and laboratories.

Sino Biological, Inc. has announced that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.

This complete next generation sequencing solution will allow laboratories to increase sequencing throughput and make reliable variant identifications.

BioChromato Inc. has published an interview that describes a new bioremediation technique developed by a leading Environmental Research Center and how the Smart Evaporator C1 offers a productive tool for preparing microbial degradation culture media for analysis.

AMSBIO has established a comprehensive portfolio of high-quality reagents including unique ranges of antibodies, lectins, enzymes, assay kits and standards, backed by in-depth technical support.

Thermo Fisher Scientific Inc. today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit, and TaqPath COVID-19 CE-IVD RT-PCR Kit, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.